Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
04 avr. 2024 08h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Arbutus to Participate in Two Upcoming Investor Conferences
08 mars 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
29 févr. 2024 07h30 HE
|
Arbutus Biopharma Corporation
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
15 févr. 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
08 janv. 2024 07h30 HE
|
Arbutus Biopharma Corporation
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a...
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
09 nov. 2023 16h01 HE
|
Arbutus Biopharma Corporation
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then...
Arbutus to Present at Jefferies London Healthcare Conference
08 nov. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
07 nov. 2023 07h30 HE
|
Arbutus Biopharma Corporation
Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV...
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
07 nov. 2023 07h15 HE
|
Arbutus Biopharma Corporation
Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the...
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
24 oct. 2023 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive...